https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39516 Wed 10 Aug 2022 11:31:35 AEST ]]> Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51272 Tue 29 Aug 2023 15:42:42 AEST ]]> Multiple Sclerosis Relapses Following Cessation of Fingolimod https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53300 Tue 21 Nov 2023 12:02:22 AEDT ]]> Prediction of multiple sclerosis outcomes when switching to ocrelizumab https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46515 Thu 24 Nov 2022 15:50:23 AEDT ]]> Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51965 Mon 25 Sep 2023 08:53:21 AEST ]]> Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53317 Fri 19 Jan 2024 14:25:45 AEDT ]]> Prediction of relapse activity when switching to cladribine for multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51076 Fri 18 Aug 2023 09:03:23 AEST ]]>